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Tumor necrosis factor alpha (TNF) is a multifunctional cyto-
kine, which possesses various biologic functions depending on
the type of the cells and the physiological context. TNF is synthe-
sized by immune cells as well as malignant cells. Accordingly,
TNF plays an important role in the tumor and microenvironment
communication as well as systemic response to the disease. TNF
gene is located at HLA class III gene locus (6p21.3) and contains
several sites of single nucleotide polymorphisms in promoter,
which modify TNF gene expression. G to A substitution at posi-
tion 238 (rs361525) decreases TNF gene expression whereas
the G to A substitution at position 308 (rs1800629) increases
the expression. Studies on the possible association of these poly-
morphisms with various malignancies risk yielded contradictory
results depending on ethnicity. Breast cancer (BC) is a multifacto-
rial disease with clinicomorphological heterogeneity. Pathways of
the main BC associated molecules (ER, PR, Her2) have crossroads
with TNF signaling. The goal of the study was to identify possible
TNF polymorphism effects on BC predisposition and prognosis in
Russian patients.
Materials and methods: DNA from 413 women with newly
diagnosed BC and 226 women without oncological, autoimmune
or inflammatory diseases (control group) was examined. Allelic
variants of 238(G/A) TNF were determined by a RFLP-PCR, the
308(G/A) TNF polymorphism was analyzed by allele-specific
PCR. Additionally Ile655Val HER2 polymorphism was tested by
RFLP-PCR in142 BC patients. The comparison of genotypes
frequencies was performed using the Fisher’s exact test. Overall
survival (OS) rate of BC patients was the criterion for estimation
of polymorphism prognostic significance and was analyzed by
the Kaplan–Meier method. The Log-rank test was used for the
comparison of different groups of patients. The difference was
considered as statistically significant at p < 0.05.
Results: A minor allele 238(A) was found in 10% BC patients
and in 7% women from control group. In the same way allele
308(A) was found with a close frequency in BC patients and con-
trols (25% and 22%). It worth to note that allele Awas found in two
position simultaneously in <1% of persons only. So, we failed to
reveal the association of both TNF polymorphisms with BC pre-
disposition. We did not reveal genotype distribution disparities
among groups with various stages of BC and the level of ER, PR
and Her2 expression. While highly active allele Val655 HER2 was
more frequent in BC patients with allele 238(A) then without
substitution (75% and 39%, accordingly, p < 0.05). We found that
10-year OS of BC patients was significantly lower in the presence
of allele 238(A) than without it in groups possessed regional
metastases (43 ± 13% and 72 ± 4%, p < 0.005) or ER + PR + tumor
(63 ± 17% and 89 ± 4%, p < 0.02). An opposite relationship was
obtained in the presence of allele 308(A) then without the
substitution when the tumor size was more than 5 cm (10-year
OS 69 ± 12% and 40 ± 8%, accordingly, p < 0.05).
Conclusions: This study found out the opposite effect of poly-
morphisms at 238 and 308 positions in TNF promoter on the
outcome of BC patients. Carriers of low expressed allele 238(A)
have poor outcome because of low response to standard hormone
therapy which presumably connected with the activation of Her2
pathway. The obtained results allow supposing that a special approach
to the treatment of this group of BC patients should be used.
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The origin of evolutionary novel genes is connected with the
origin and evolution of the novel organismal functions and the
increase in morphological complexity of multicellular organisms.
Novel gene acquire new or altered functions. Here we describe
that evolutionary novel genes, expressed predominantly in trans-
genic fish tumors after their induced regression, determine pro-
gressive evolutionary characters and are conserved in human.
We used a sample of genes, which were activated in inducible
krasV12 transgenic zebrafish tumors according to the results of
RNASeq data. Genes from our sample were expressed after HCC
regression upon kras inactivation. The search of orthologs by dif-
ferent tools, such as blastx and psiblast, with e-value cut off not
less than 10–3 and query coverage more than 50%, discovered that
considerable proportion of tumor-specifically expressed genes are
evolutionary novel, i.e. their orthologs are not found in Lamprey.
Nine tenths of these novel genes have orthologs in humans. Gene
ontology (GO) data were used to analyze their functions. Accord-
ing to the results of GO, some of the genes have functions not
characteristic to fish. Among known functions of the human
orthologues of evolutionary novel genes of zebrafish (vs. Lam-
prey) there are some important morphogenetic functions. For
example, genes ccdc40, lmx1ba and lepa acquired functions in
lung, embryonic utera and placenta, i.e. organs originated in taxa
higher than fish. A large proportion of genes from our sample are
connected with retina type eye, heart and brain development.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.064
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Glioblastoma is one of the most malignant cancer types. Its
median survival is 15 months with combined radio- and
chemotherapy and only 4 months without therapy. Molecular
chaperones play a very multifaced role in tumor development.
Depletion of Hdj1 in cancer cells accelerates tumor growth.
Decrease of Hdj2 level correlates with the increase of tumor
aggressiveness, but also attenuates tumor protection against
radiotherapy. Hsp70 provides considerable survival advantages
to the cancer cells, but at the same time can act as a
‘‘chaperokine”, activating antitumoral immunity. For assessment
of chaperone’s role in glioma progression, invasiveness and
metastasis formation we chose rat model of intracranial injection
of 105 C6 cells. We developed three C6-based cell lines with
protein knock-down by RNA-interference: C6 shHsp70 (on 83%),
C6 shHdj1 (on 96%) and C6 shHdj2 (on 52%). The last differed in
roundish and easily detachable morphology. Following intracra-
nial injection of the modified tumor cells, the animals’ survival
was estimated. As compared to the groups of control C6 (25.4
± 3.9 days) and C6 shHdj1 (25.5 ± 3.8) we observed a nearly 1.5-
fold decrease in survival in C6 shHdj2 (16.8 ± 3.5 days) (P < 0.05).
On the contrary, in C6 shHsp70 group the survival increased up
to 42.5 ± 12.0 days (the increase is completely explainable by the
slower growth rate of the culture). Subsequent MR imaging and
histological analysis of tumors demonstrated elevated invasive-
ness and metastatic activity in C6 shHdj2 group in comparison
to C6 shHsp70, C6 shHdj1 and control C6. High migration activity
and the ability of floating C6 shHdj2 cells to adhere and settle on
the substrate was proved in wound-healing assay, spot-healing
assay, colony forming assay and transwell migration assay. Adhe-
sion assay showed decreased adhesion ability of C6 shHdj2 cells
and increased – of C6 shHsp70 cells on all types of tested extracel-
lular matrixes. Immunofluorescence analyses showed loss of
membrane- expressed N-cadherin and loss of intercellular con-
tacts mediated by N-cadherin in C6 shHdj2 cells in comparison
to other considered cell lines (although its level in western blot
was elevated). Actin staining with rhodamine-falloidin revealed
highly abundant leading edges in C6 shHdj2 culture. Matrix met-
alloprotease zymography proved an increased activity in gelati-
nases (mmp2 and mmp9) as well as in caseinases (mmp1 and
mmp8) in C6 shHdj2 culture supernatant. Assay of stemness mar-
ker CD133 expression showed its 11.8 times increase in C6 shHdj2.
Our experiments proved the high importance of Hdj2 level in
glioma progression, invasion and metastasis.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.065
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Background: multidrug resistance (MDR) remains a major
problem in the fight against tumors. MDR – multidimensional
phenomenon, which occurs as a consequence of activation of
several systems, associated both with the release of xenobiotics
from the cell by ABC-transporters, and with stimulation of path-
ways that enhance cell survival. One of the possible regulators of
MDR is multifunctional protein YB-1. YB-1 acting as a transcrip-
tion factor in cell’s nucleus, can upregulate expression of MDR1,
as well as some other ABC-transporters genes. Furthermore, YB-
1 is secreted by cells and binds to the protein Notch3, and that
stimulates proliferation and migration of cells. Also, resistance
of cells may increase upon stimulation of VEGF-VEGER systems.
Our aim was to study the mechanisms of MDR at various levels
in the pairs of parental and resistant breast cancer cells: changes
in the expression and localization of YB-1, evaluation expression
of ABC-transporters, activation of protein Notch, as well as
changes in the VEGF system.
Materials and methods: Long-term cultivation of cells MCF-7
(breast adenocarcinoma) and HBL-100 (transformed cells) in the
presence of doxorubicin to obtain resistant sublines, MTT assay,
real-time PCR, immunocytochemistry, flow cytofluorometry.
Results: we obtained the sublines of cells MCF-7 and HBL-
100 resistant to doxorubicin: MCF-7/D7 and HBL-100/D85,
respectively. The level of resistance to doxorubicin in resistant
MCF-7/D6 was 7 times higher than in parent MCF-7 (IC50 was
0.7 ± 0.01 mcM vs 0.1 ± 0.002 mcM, respectively), and the level
of resistance HBL-100/D85 was 44.7 times higher than the
HBL-100 (IC50 8.5 ± 0.17 mcM vs 0.19 ± 0.03 mcM). Also, MCF-7/
D7 acquired cross-resistance to cisplatin (6.7 ± 0.1 mcM vs
48 ± 0.2 mcM) and paclitaxel (2 ± 0.03 nM vs 50 ± 1 nM), but
not to vinblastine and 5-fluorouracil, and HBL-100/D85 – about
100 times to paclitaxel (13 ± 0.2 nM vs 1100 ± 19 nM) and vin-
blastine (2.4 ± 0.3 nM vs 250 ± 5 nM), but not to the cisplatin
and 5-fluorouracil. The expression profile of ABC-transporter
genes showed significant activation of the MDR1 expression
in subline HBL-100/D85 (more than 1000 times), but not in
MCF-7/D6.
Expression of other genes of the family ABC-transporters -
MRP1, BCRP, MVP - increased slightly. Expression of mRNA YB-1
was almost unchanged. YB-1 protein detected in cytoplasm of
parental lines, but it detected in nuclei in resistant sublines. Also,
protein Notch3 translocated from membrane into nucleus. Evalu-
ation of VEGF expression profile revealed that in a couple of
VEGFA-VEGFR2 didn’t occur any changes. However, we observed
a significant upregulation of expression mRNA VEGFC and
down-regulation of mRNA VEGFR3 in resistant sublines MCF-7/
D6 and HBL-100/D85.
Conclusion: the results of our study show that the appear-
ance of MDR associated with various changes in cells. Com-
mon changes in the resistant sublines were translocation of
protein YB-1 and Notch3 in cells nuclei, as well as the dynam-
ics of expression changes in pair VEGFCVEGFR3.The last obser-
vation is an interesting finding and requires more detailed
study.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.066
EJC SUPPLEMENTS 13 (2015) 1–75 37
